Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals

Claim extract · Listening Library

Capone / VETS interviews: veteran PTSD–TBI advocacy vs observational evidence

LAST REVIEWED 2026-09-22 · ADVOCACY MEDIA · OBSERVATIONAL PRIMARY

Marcus and Amber Capone appear across high-reach podcasts describing lived experience and VETS advocacy. Separate first-person narrative from peer-reviewed observational findings and from FDA / Schedule I status.

Veteran advocacy mediaObservational ≠ RCTNo clinic referrals

Listening Library sources (outbound)

Testable claims extracted (media → primary)

  1. Claim (media / advocacy): Magnesium–ibogaine observational work in special-operations veterans shows promising TBI / PTSD symptom signals.
    Primary (open-label observational): Cherian KN et al., Nat Med 2024. PMID 38182784, DOI 10.1038/s41591-023-02705-w. Label: n=30 open-label — hypothesis-generating, not broad proof.
  2. Claim (media critique needed): Podcast framing can overstate what an observational cohort establishes.
    Primary (method critique): Gorman 2026. PMID 42330793. See Stanford critique card.
  3. Claim (neuroimaging adjacency): Later veteran neuroimaging extends the same stream without converting it into confirmatory RCTs.
    Primary: Sridhar M et al., Biol Psychiatry Cogn Neurosci Neuroimaging 2026. PMID 41687815, DOI 10.1016/j.bpsc.2026.02.001.
  4. Claim (overclaim): Advocacy urgency means ibogaine is FDA-approved for PTSD or TBI.
    Verdict: False — FDA check + PTSD / TBI.

Verdict

Advocacy media is high-signal for policy attention; it is not a substitute for denominators, controlled trials, or cardiac-risk literacy. IbogaBase does not refer to clinics or reproduce regimens.

Continue reading